Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA requests more information on Avanir drug
Pseudobulbar affect is a condition that sometimes affects multiple sclerosis sufferers, leaving them unable to control their emotions. The agency requested that the company provide an expansion of
Pseudobulbar affect is a condition that sometimes affects multiple sclerosis sufferers, leaving them unable to control their emotions. The agency requested that the company provide an expansion of
The study objectives were to evaluate the safety, tolerability, and pharmacokinetics of escalating single oral doses of NG2-73 in healthy male and female subjects. Each cohort of subjects
The grant comes from the Defense Advanced Research Projects Agency, of the US Department of Defense. Conventional vaccine development and manufacturing methods require years of effort after the
Under the terms of the agreement, Illumina will use Sentrix Arrays in conjunction with the company’s GoldenGate and Infinium assays to conduct genetic studies for thousands of samples
The drug did demonstrate effectiveness in the indication; however results from the trial showed that the amount of drug needed to achieve the desired anticoagulation for use in
Cystic Fibrosis Foundation Therapeutics, a nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is supporting this trial with study-specific funding of up to $2.35 million
“The FDA’s Fast Track designation is a significant endorsement of the sizeable medical need for a product like MC-1,” commented Medicure’s president and CEO, Dr Albert Friesen. “The
Based on its discovery of a disease-causing molecule found only in the joints of RA patients, MaimoniDex has developed a murine monoclonal antibody that has shown bioactivities both
Lyrica has a newly defined mechanism of action and represents an important treatment advance. It is the first treatment approved by the FDA to treat two distinct forms
The first phase I trial will investigate the efficacy of XL844 in patients with chronic lymphocytic leukemia, the second trial for a compound labeled XL184 will be conducted